Effect of four oral contraceptives on hemostatic parameters
article
OA: closed
CC0
⤵ 23 in-corpus citations
AI-generated summary
This study investigated the effects of four different oral contraceptives on various hemostatic parameters in women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This is the first double-blind, controlled, randomized study comparing the effect of different estrogen components in oral contraceptives (OCs) on hemostasis variables. Four groups of 25 women each were treated for six cycles with monophasic combinations containing 21 tablets with either 30 microg ethinylestradiol (EE) + 2 mg dienogest (DNG) (30EE/DNG), 20 microg EE + 2 mg DNG (20EE/DNG), 10 microg EE + 2 mg estradiol valerate (EV) + 2 mg DNG (EE/EV/DNG) or 20 microg EE + 100 microg levonorgestrel (LNG) (EE/LNG). Blood samples were taken on Days 21-26 of the control cycle and on Days 18-21 of the first, third and sixth treatment cycle. Treatment with all four OCs caused an increase in levels of fibrinogen, prothrombin fragment 1+2, D-dimer, plasminogen, plasmin-antiplasmin complex and an increase in protein C activity, a decrease in antithrombin activity, tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI), and a slight decrease in the sensitivity to activated protein C, but no significant change in that of the thrombin-antithrombin complex. In users of the DNG-containing OCs, the reduction in total and free protein S, and in t-PA and PAI was dependent on the EE dose, while factor VII activity was elevated, but not significantly different from EE/LNG. The results are in agreement with those of previous studies. The effects of EE/EV/DNG on total and free protein S and on t-PA and PAI were lower than those of 20EE/DNG, suggesting that the impact of 2 mg EV on several hemostasis variables is less than that of 10 microg EE. The results show an antagonistic effect of LNG on the EE-induced rise of factor VII activity and fragment 1+2 and on the EE-dependent reduction of total and free protein S.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (70)
- Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system via openalex
- Effect of dienogest-containing oral contraceptives on lipid metabolism via openalex
- doi:10.1055/s-0037-1613960 via openalex
- doi:10.1055/s-0038-1646528 via openalex
- doi:10.1016/0010-7824(89)90116-9 via openalex
- doi:10.1016/s0140-6736(94)90286-0 via openalex
- doi:10.1161/hc4801.099737 via openalex
- doi:10.1016/s0140-6736(75)92292-8 via openalex
- doi:10.1016/0010-7824(94)90051-5 via openalex
- doi:10.1016/0378-5122(93)90119-3 via openalex
- doi:10.1016/s0002-9378(99)70366-2 via openalex
- doi:10.1016/0002-9378(90)90585-u via openalex
- doi:10.1055/s-0038-1649632 via openalex
- doi:10.1016/s0010-7824(97)00119-4 via openalex
- doi:10.1093/humrep/13.11.2981 via openalex
- doi:10.3109/00365528709089754 via openalex
- doi:10.1093/humrep/16.1.3 via openalex
- doi:10.1016/0002-9378(91)91424-u via openalex
- doi:10.1136/bmj.2.5753.73 via openalex
- doi:10.1016/0010-7824(89)90070-x via openalex
- doi:10.1016/s0002-9378(98)70293-5 via openalex
- doi:10.1182/blood-2002-10-3188 via openalex
- W1449069762 via openalex
- doi:10.1016/s0002-9378(99)70721-0 via openalex
- doi:10.3109/09513599609012318 via openalex
- doi:10.1016/s0002-9378(16)32484-x via openalex
- doi:10.1111/j.1365-2141.1988.tb04232.x via openalex
- doi:10.1111/j.1365-2141.1988.tb07631.x via openalex
- doi:10.1055/s-0038-1650300 via openalex
- doi:10.1097/00001721-199210000-00031 via openalex
- doi:10.1055/s-0038-1650651 via openalex
- doi:10.1046/j.1365-2141.1997.192707.x via openalex
- doi:10.1016/s0140-6736(99)06092-4 via openalex
- doi:10.1136/bmj.306.6883.956 via openalex
- doi:10.1093/oxfordjournals.aje.a115799 via openalex
- doi:10.1055/s-0037-1612973 via openalex
- doi:10.1111/j.1471-0528.1991.tb15364.x via openalex
- doi:10.1136/bmj.323.7305.131 via openalex
- doi:10.1016/s0049-3848(98)90006-8 via openalex
- W2129715334 via openalex
- doi:10.3109/13625189909040809 via openalex
- doi:10.1016/0010-7824(95)00271-5 via openalex
- doi:10.1016/0049-3848(93)90135-b via openalex
- W2164372236 via openalex
- doi:10.1182/blood.v93.4.1271 via openalex
- W2231098098 via openalex
- W2275376451 via openalex
- W2277618799 via openalex
- W2289080121 via openalex
- W2294022362 via openalex
- W2300692921 via openalex
- doi:10.1007/978-981-16-1037-0_16 via openalex
- doi:10.1007/bf01849494 via openalex
- doi:10.1016/s0010-7824(02)00388-8 via openalex
- doi:10.3109/01443619509015499 via openalex
- doi:10.1016/s0002-9378(12)90880-7 via openalex
- doi:10.1007/978-94-011-2992-3 via openalex
- doi:10.1093/humrep/17.12.3235 via openalex
- doi:10.1016/0378-5122(96)00994-2 via openalex
- doi:10.1016/s0140-6736(99)80017-8 via openalex
- doi:10.1016/s0002-9378(87)80129-1 via openalex
- doi:10.1016/s0010-7824(98)00045-6 via openalex
- doi:10.1016/s0010-7824(98)00014-6 via openalex
- doi:10.1053/ob.1998.v179.a92633 via openalex
- doi:10.1111/j.1365-2141.1999.01302.x via openalex
- doi:10.1055/s-0038-1651554 via openalex
- doi:10.1111/j.1471-0528.1996.tb09716.x via openalex
- doi:10.1016/s0010-7824(02)00476-6 via openalex
- doi:10.1136/bmj.323.7303.1 via openalex
- doi:10.1016/0002-9378(90)90596-y via openalex
Cited by (16)
- Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under 2020
- Impact of estrogen type on cardiovascular safety of combined oral contraceptives 2016
- The influence of oral combined oral contraceptive with estradiol valerate and dienogest on hemostatic system 2015
- The influence of oral combined oral contraceptive with estradiol valerate and dienogest on hemostatic system (a review) 2015
- Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol 2014
- An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest 2012
- Estradiol Valerate and Dienogest: A Novel Four-Phasic Oral Contraceptive Pill Effective for Pregnancy Prevention and Treatment of Heavy Menstrual Bleeding 2011
- Estradiol Valerate/Dienogest: A Novel Oral Contraceptive 2011
- Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive 2011
- Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive 2011
- Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill 2010
- Review of clinical experience with estradiol in combined oral contraceptives 2009
- Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial 2009
- Original research article Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies ☆,☆☆ 2008
- Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters 2008
- New progestagens for contraceptive use 2005
Source provenance
- openalex
- last seen: 2026-05-11T06:21:44.532445+00:00
License: CC0
· commercial use OK